论文部分内容阅读
目的： 观察尿激酶静脉溶栓治疗急性脑梗死的临床有效性及安全性。方法： 应用大剂量尿激酶超早期（发病6小时内）静脉溶栓治疗急性脑梗死23例，于溶栓前及溶栓后2小时、24小时、1个月进行神经功能缺损评分，同时观察脑内及其它系统有无出血并发症。结果： 溶栓后2小时瘫痪肢体肌力提高3级4例，2级8例，1级7例，无变化4例，其中4例24小时内临床症状反复；1个月时，发病4小时内溶栓组与4小时至6小时内溶栓组相比，神经功能缺损评分值（ESS）升高更明显，前者P ＜0．01，后者P ＜0．05，本组有1例大面积脑梗死溶栓后出现非症状性出血性脑梗死，3例于溶栓结束后出现轻微齿龈出血，无1例死亡。结论：大剂量尿激酶静脉溶栓治疗急性脑梗死其疗效较肯定，溶栓开始时间越早，疗效越好，在严格掌握适应证情况下，应用比较安全。
Objective: To observe the clinical efficacy and safety of intravenous thrombolytic therapy of urokinase in acute cerebral infarction. Methods: 23 cases of acute cerebral infarction were treated by intravenous thrombolysis with high-dose urokinase ultra-early (within 6 hours of onset), neurological deficit scores were measured before thrombolysis and 2 hours, 24 hours and 1 month after thrombolysis Brain and other systems with or without bleeding complications. Results: After 2 hours of thrombolytic therapy, limb muscle strength was increased in 3 cases in 4 cases, in 2 cases in 8 cases and in 1 case in 7 cases, with no change in 4 cases, of which 4 cases repeated clinical symptoms within 24 hours; at 1 month, onset of 4 hours Thrombolytic group within 4 hours to 6 hours compared with thrombolytic group, neurological deficit score (ESS) increased more significantly, the former P <0.01, the latter P <0.05, the group of 1 case Non-symptomatic hemorrhagic cerebral infarction occurred after thrombolysis in a large area of cerebral infarction, and slight gingival bleeding occurred in 3 cases after the thrombolysis. None of them died. Conclusion: The high dose of urokinase intravenous thrombolytic therapy in patients with acute cerebral infarction its efficacy is more positive, the earlier the thrombolysis start, the better the effect, in the strict indications of indications, the application of safer.